The FDA has granted priority review to giredestrant for the treatment of early breast cancer that is estrogen receptor-positive and HER2-negative. The application is for a potential treatment to reduce the risk of recurrence or death in this type of breast cancer, with some reports suggesting it may lower this risk by a significant percentage. The review is for a new drug application submitted by Genentech, a company owned by Roche, for an oral medication that has shown positive results in phase III trials.